Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
出版年份 2018 全文链接
标题
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 100, Issue 5, Pages 494-501
出版商
Wiley
发表日期
2018-02-17
DOI
10.1111/ejh.13046
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
- (2017) Vishal Bhatnagar et al. ONCOLOGIST
- Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
- (2016) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
- (2016) T. Plesner et al. BLOOD
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis
- (2016) Taimur Sher et al. BLOOD
- What is new in diagnosis and management of light chain amyloidosis?
- (2016) G. Palladini et al. BLOOD
- Monoclonal antibodies — A new era in the treatment of multiple myeloma
- (2016) Tomas Jelinek et al. BLOOD REVIEWS
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma
- (2016) Wilson I. Gonsalves et al. LEUKEMIA RESEARCH
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
- (2015) T Narita et al. Blood Cancer Journal
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
- (2014) I. S. Nijhof et al. CLINICAL CANCER RESEARCH
- Light chain amyloidosis 2012: a new era
- (2013) Moshe E. Gatt et al. BRITISH JOURNAL OF HAEMATOLOGY
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
- (2012) R L Comenzo et al. LEUKEMIA
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders
- (2010) Karthick R. M. Raja et al. BRITISH JOURNAL OF HAEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started